Bibliographie Cannabis et Troubles cardio-vasculaires Dr Christian SUEUR, GRECC, 2e édition, janvier 2020. Actuellement, les méta-analyses ne montrent pas d'augmentation significative des pathologies cardiovasculaire chez les consommateurs de cannabis. (cf en particulier la méta-analyse de Divya RAVI et coll., Annals of Internal Medicine, 2018). Quoiqu'il en soit, l'existence de facteurs de risques liés à la consommation de cannabis fumé est semble-t-il incontestable; de même, les risques sont vraisemblablement augmentés chez les sujets prédisposés, présentant des pathologies cariaques, vasculaires, des troubles de l'excitabilité cardiaque ou de la tension artérielle. La plupart des "Case Report" consistent en des accidents par sténose vasculaire, cérébrale ou cardiaque, [...]
Lire la suiteCharacterising heterogeneity in the use of different cannabis products : latent class analysis with 55 000 people who use cannabis and associations with severity of cannabis dependence Sam Craft, Adam Winstock, Jason Ferris, Clare Mackie, Michael T. Lynskey and Tom P. Freeman Psychological Medicine, 2019, 1–10. doi : 10.1017/S0033291719002460 Abstract Background. As new cannabis products and administration methods proliferate, patterns of use are becoming increasingly heterogeneous. However, few studies have explored different profiles of cannabis use and their association with problematic use. Methods. Latent class analysis (LCA) was used to identify subgroups of past-year cannabis users endorsing distinct patterns of use from a large international sample [...]
Lire la suiteBeta-Caryophyllene, a CB2-Receptor-Selective Phytocannabinoid, Suppresses Mechanical Allodynia in a Mouse Model of Antiretroviral-Induced Neuropathic Pain Esraa Aly, Maitham A. Khajah and Willias Masocha Molecules, 2020, 25, 106; doi:10.3390/molecules25010106 Abstract : Neuropathic pain associated with nucleoside reverse transcriptase inhibitors (NRTIs), therapeutic agents for human immunodeficiency virus (HIV), responds poorly to available drugs. Smoked cannabis was reported to relieve HIV-associated neuropathic pain in clinical trials. Some constituents of cannabis (Cannabis sativa) activate cannabinoid type 1 (CB1) and cannabinoid type 2 (CB2) receptors. However, activation of the CB1 receptor is associated with side eects such as psychosis and physical dependence. Therefore, we investigated the effect of B-caryophyllene (BCP), [...]
Lire la suiteProlonged Cannabidiol Treatment Lacks on Detrimental Effects on Memory, Motor Performance and Anxiety in C57BL/6J Mice Eva M. Schleicher, Frederik W. Ott, Melanie Müller, Barbara Silcher, Marius E. Sichler, Maximilian J. Löw, Jannek M. Wagner and Yvonne Bouter Frontiers in Behavioral Neuroscience, 2019, Volume 13, Article 94 doi : 10.3389/fnbeh.2019.00094 The Cannabis plant contains more than 100 currently known phytocannabinoids. Regarding the rising consumption of the non-psychotropic phytocannabinoid cannabidiol (CBD) in people’s everyday life (e.g., beauty products, food and beverages), the importance of studies on the influence of CBD on healthy humans and rodents is evident. Therefore, the behavioral profile of CBD was investigated with [...]
Lire la suite'Standard THC units': a proposal to standardize dose across all cannabis products and methods of administration T.P. Freeman, V.Lorenzetti Addictions, 2019, Oct 12. doi : 10.1111/add.14842 © 2019 Society for the Study of Addiction. Abstract BACKGROUND AND AIMS : Cannabis products are becoming increasingly diverse, and vary considerably in concentrations of ∆9 -tetrahydrocannabinol (THC) and cannabidiol (CBD). Higher doses of THC can increase the risk of harm from cannabis, while CBD may partially offset some of these effects. Lower Risk Cannabis Use Guidelines currently lack recommendations based on quantity of use, and could be improved by implementing standard units. However, there is currently no consensus on [...]
Lire la suiteBibliographie CANNABINOÏDES et Traitement des Nausées et Vomissements Docteur Christian SUEUR, GRECC, 2e édition, janvier 2020. Le Cannabis comme anti-émétique : Les prescriptions médicales, chez les adultes (THC naturel ou synthétique - Nabilone) comme chez les enfants (delta 8-THC, Abrahamov et al, 1995), ont débutées dès 1975. L’efficacité a été prouvée dans de nombreux essais cliniques, et de nombreuses méta-analyses (8/9 pour le cannabis et 3/3 pour le Nabilone, Penta et al, 1981). Par contre les effets psychotropiques peuvent être mal supportés par de nombreux patients, et justifie l’arrêt, ou la diminution des doses. Les associations variables THC/CBD présente un intérêt probable. Aucun effet indésirable persistant ou fatal [...]
Lire la suiteA behavioural comparison of acute and chronic D9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice Leonora E. Long, Rose Chesworth, Xu-Feng Huang, Iain S. McGregor, Jonathon C. Arnold and Tim Karl International Journal of Neuropsychopharmacology, 2010, 13, 861–876. doi : 10.1017/S1461145709990605 Abstract Cannabis contains over 70 unique compounds and its abuse is linked to an increased risk of developing schizophrenia. The behavioural profiles of the psychotropic cannabis constituent D9 tetrahydro-cannabinol (D9-THC) and the non-psychotomimetic constituent cannabidiol (CBD) were investigated with a battery of behavioural tests relevant to anxiety and positive, negative and cognitive symptoms of schizophrenia. Male adult C57BL/6JArc mice were given 21 daily intraperitoneal injections of vehicle, [...]
Lire la suiteA reliable and validated LC-MS/MS method for the simultaneous quantification of 4 cannabinoids in 40 consumer products Qingfang Meng, Beth Buchanan, Jonathan Zuccolo, Mathieu-Marc Poulin, Joseph Gabriele, David Charles Baranowski PLoS ONE, 2018, 13, (5), e0196396. https://doi.org/10.1371/journal.pone.0196396 Abstract In the past 50 years, Cannabis sativa (C. sativa) has gone from a substance essentially prohibited worldwide to one that is gaining acceptance both culturally and legally in many countries for medicinal and recreational use. As additional jurisdictions legalize Cannabis products and the variety and complexity of these products surpass the classical dried plant material, appropriate methods for measuring the biologically active constituents is paramount to ensure [...]
Lire la suiteSingle Shot of Ketamine May Herald 'Last Call' for Problem Drinking Deborah Brauser Medscape, December 11, 2019 Medscape Medical News © 2019 https://www.medscape.com/viewarticle/922460?src=wnl_tp10n_200116_mscpedit&uac=292598PZ&impID=2238619&faf=1 An experimental treatment that includes a single infusion of ketamine may lead to long-term improvement in problem drinking, new research suggests. In an study of 90 heavy drinkers, those who received a single dose of intravenous (IV) ketamine plus cognitive behavioral therapy (CBT) that focused on reactivating drinking-related "maladaptive reward memories" (MRMs) significantly curbed the urge to drink and reduced alcohol intake compared with those who received the ketamine alone or a placebo infusion. In addition, the combination group reduced their average weekly alcohol consumption by [...]
Lire la suiteIsolation of a High Affinity Cannabinoid for Human CB1 Receptor from a Medicinal Cannabis Variety: Δ9-Tetrahydrocannabutol, the Butyl Homologue of Δ9-Tetrahydrocannabinol Pasquale Linciano, Cinzia Citti, Livio Luongo, Carmela Belardo, Sabatino Maione, Maria Angela Vandelli, Flavio Forni, Giuseppe Gigli, Aldo Laganà, Carmela Maria Montone, Giuseppe Cannazza Journal of Natural Products, 2019 Dec 31. doi: 10.1021/acs.jnatprod.9b00876. Abstract The butyl homologues of Δ9-tetrahydrocannabinol, Δ9-tetrahydrocannabutol (Δ9-THCB), and cannabidiol, cannabidibutol (CBDB), were isolated from a medicinal Cannabis sativa variety (FM2) inflorescence. Appropriate spectroscopic and spectrometric characterization, including NMR, UV, IR, ECD, and HRMS, was carried out on both cannabinoids. The chemical structures and absolute configurations of the isolated cannabinoids were [...]
Lire la suite